SCHEMBL65861

SCHEMBL65861

N#Cc1cccc(S(=O)(=O)Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.50
MCOLN3 Q8TDD5 1/20 0.48
PGR P06401 1/20 0.47
ALDH1A1 P00352 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TRPV4 Q9HBA0 2/20 0.45
KAT6A Q92794 2/20 0.44
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44
GLO1 Q04760 1/20 0.44
SLC40A1 Q9NP59 1/20 0.44
ACLY P53396 2/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 1/20 0.43
BRD4 O60885 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28685956 0.83 IDO1 (0.48) MCOLN3PGRKAT6AGLO1SLC40A1
SCHEMBL1891657 0.82 MCOLN3 (0.49) ENPP2MCOLN3PGRKAT6ACTSG
SCHEMBL7380869 0.82 ALDH1A1 (0.48) MCOLN3PGRALDH1A1HSD17B10TDP1
SCHEMBL30915555 0.80 MCOLN3 (0.51) ENPP2MCOLN3PGRKAT6ACTSG
SCHEMBL410063 0.80 MCOLN3 (0.51) ENPP2MCOLN3PGRKAT6ACTSG
SCHEMBL791765 0.80 CA2 (0.67) MCOLN3PGRCA12CA1CA2
SCHEMBL4574069 0.80 KAT6A (0.48) ENPP2MCOLN3PGRKAT6ACTSG
SCHEMBL31672139 0.80 CA1 (0.67) ALDH1A1HSD17B10TDP1CA12CA1
SCHEMBL1487652 0.80 TSHR (0.52) ENPP2MCOLN3PGRALDH1A1HSD17B10
SCHEMBL4894331 0.80 MCOLN3 (0.51) ENPP2MCOLN3PGRKAT6ACTSG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119425423-A Positively charged composite membrane and preparation method and application thereof 中国石油化工股份有限公司 2025-02-14 CN claimed
CN-103709089-B One prepares the method for 3-(4 '-chlorobutyl)-5-cyanoindole NANTONG HENGSHENG FINE CHEMICAL CO., LTD. (CN) 2015-08-19 CN claimed
CN-104678028-A Pretreatment and detection method for biogen amine neurotransmitter and detection kit INST PHARM & TOXICOLOGY AMMS 2015-06-03 CN claimed
EP-2385831-A2 SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT The UAB Research Foundation (US) 2011-11-16 EP claimed
US-20110254866-A1 INFORMATION PROCESSING APPARATUS, METHOD AND PROGRAM THEREFORE SONY CORPORATION (JP) 2011-10-20 US claimed
WO-2010123591-A2 SMALL MOLECULE INHIBITORS OF NADS, NAMNAT, AND NMNAT THE UAB RESEARCH FOUNDATION (US) 2010-10-28 WO claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 US disclosed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
EP-4684803-A1 ANTIBODY CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF RBM39 AND THERAPEUTIC USES THEREOF CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) 2026-01-28 EP disclosed
US-20260001864-A1 COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION NANJING SHUOHUI PHARMATECHNOLOGY CO., LTD (CN) 2026-01-01 US disclosed
US-12410210-B2 Neuroactive steroids and their methods of use SAGE THERAPEUTICS, INC. (US) 2025-09-09 US disclosed
EP-4596534-A1 NONCOVALENT SMALL-MOLECULE INHIBITORS OF THE KEAP1-NRF2 INTERACTION University of Copenhagen (DK) 2025-08-06 EP disclosed
EP-4581011-A1 NOVEL SELECTIVE INHIBITORS OF LYSYL OXIDASES Syntara Limited (AU) 2025-07-09 EP disclosed
US-5767283-A CHEMICAL INTERMEDIATE FOR 7-N-ORGANOSULFONYL-1H-INDOLE DERIVATIVE ANTITUMOR AGENTS; NONTOXIC EISAI CO., LTD. (JP) 1998-06-16 US disclosed
US-5721246-A ANTITUMOR AGENTS; LOW TOXICITY EISAI CO., LTD. (JP) 1998-02-24 US disclosed
WO-1997045403-A1 ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1997-12-04 WO disclosed
EP-0807101-A1 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1997-11-19 EP disclosed
WO-1997036580-A1 AMIDINOHYDRAZONES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1997-10-09 WO disclosed
WO-1996023760-A1 2-AMINOINDANS AS SELECTIVE DOPAMINE D3 LIGANDS PHARMACIA & UPJOHN COMPANY (US) 1996-08-08 WO disclosed
EP-0673937-A1 BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES Eisai Co., Ltd. (JP) 1995-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410210-B2 Neuroactive steroids and their methods of use NR3C2, MC2R, NR3C1 ENPP2 1716/4885MCOLN3 2662/4885PGR 251/4885
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 ENPP2 4077/4885MCOLN3 3780/4885PGR 3805/4885
US-20260001864-A1 COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION SLC10A2, SLC6A11, ABCB11 ENPP2 3297/4885MCOLN3 2535/4885PGR 744/4885
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 ENPP2 3779/4885MCOLN3 4468/4885PGR 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.